eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
https://grassfed.us/Sedler-neighbour-of-Leialoha-from-Kitchener in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
. severe psoriasis. credit: penn medicine
.